Detailed Narrative
Strong FY26 Performance Driven by Deleveraging and Profitability
UPL reported robust full-year FY26 results, with revenue growing 11% to INR52,000 crores and EBITDA increasing 18% YoY, surpassing initial guidance. This performance was underpinned by significant deleveraging, as net debt reduced by $400 million to $1.6 billion, bringing the net debt to EBITDA ratio below 1.6x from 4.6x in FY24. The company also saw its Profit Before Tax multiply fourfold to INR3,200 crores and operational PATMI grow 2.5x to INR1,900 crores, reflecting improved bottom-line performance.
Strategic Focus on Innovation and Differentiated Portfolio
Innovation remains a core driver, with UPL launching over 300 new products in FY26, contributing over $160 million in revenue and increasing the innovation rate (products introduced in the last five years) to 16%. The company is actively shifting its mix towards higher-margin differentiated and sustainable solutions, particularly within its Natural Plant Protection (NPP) business. The NPP segment is targeted to reach $700 million in revenue in FY27 and $1 billion by FY31, supported by a pipeline valued at $4.4 billion at peak sales, with 80% comprising differentiated solutions.
Segmental Growth and Mix Shift Towards Specialty Chemicals
All major platforms contributed to growth, with Advanta's top line growing 23% and UPL Corp's global crop protection business growing 11% in FY26. Notably, SUPERFORM's specialty chemicals segment grew 20% YoY, increasing its share of SUPERFORM's revenue from 20% to 28%. This strategic mix shift is expected to drive SUPERFORM's EBITDA margin to 20% within the next 48 months, up from the current 12.2%, as the company focuses on higher-value offerings.
Disciplined Capital Allocation and Liquidity Management
UPL demonstrated disciplined capital allocation by repaying $500 million of loans and redeeming $400 million of perpetual bonds using internal accruals, reducing gross debt by $850 million. The company also extended a $400 million loan by three years and secured a $300 million revolving credit facility, ensuring ample liquidity. Capex for FY26 was $261 million, slightly above the $250 million guidance, with plans to increase FY27 capex to $300-350 million to capitalize on opportunities in specialty chemicals and backward integration.
Cautious FY27 Q1 Outlook Amidst Market Headwinds
For Q1 FY27, UPL provided a revenue growth guidance of 10-14% and an EBITDA growth guidance of 14-18%. Management noted that Q1 is typically a slower quarter and that while FX impacts revenue more significantly, its effect on EBITDA is lesser (6-7%). The company acknowledged ongoing market volatility🌐, including potential impacts from the Middle East crisis and raw material price fluctuations, but expressed confidence in its ability to adapt through disciplined sourcing and agile supply chain management.
Investor Feedback on Reorganization and Sinova Investment
Management acknowledged significant investor feedback regarding the recently announced reorganization structure, particularly concerns about a potential HoldCo discount and shareholder dilution. They committed to presenting this feedback to the board for further review within a month or two. Additionally, UPL confirmed a $87 million primary infusion into Sinova, a strategic joint venture, to support its growth in UPL Brazil, clarifying the nature and rationale of the investment as a distribution company with 4-6% margins.